Aligos Therapeutics Liver Disease Updates Coming at Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company...
Disease
COVID-19 Linked to Development of Chronic Kidney Disease Months After Illness
Previous research has found that patients are more likely to develop acute kidney injury while they have COVID-19 and in...
Thousands to benefit from new kidney disease treatment
Thousands of people living with chronic kidney disease in England could soon benefit from a new treatment, following final draft...
![Surviving kidney disease and reforming patient care [PODCAST]](https://kevinmd.com/wp-content/uploads/Design-2-scaled.jpg "Surviving kidney disease and reforming patient care [PODCAST]")
Surviving kidney disease and reforming patient care [PODCAST]
Subscribe to The Podcast by KevinMD. Watch on YouTube. Catch up on old episodes! Health care executive and patient advocate...
4D flow MRI shows promise in chronic liver disease
4D flow MRI reflects vascular changes associated with the progression of fibrosis in patients with chronic liver disease, according to...
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
Affecting up to 5% of the global population, SLD represents an area of significant unmet medical need with limited treatment...
